Liver metastases from breast cancer LMBC are typically considered to indicate systemic disease spread and patients are most often offered systemic palliative treatment only.
liver cancer breast Rfa metastasis
As an additional efficacy descriptor beyond RECIST, control of LMBC by interventional treatment during follow-up was used, with patients demonstrating either overall objective response, stable disease, or limited disease progression amenable to repeat local ablation being regarded as having controlled disease. Tumors that may be treated by RFA include: Hepatoma primary liver cancer. Nat Rev Clin Oncol. Rossi S. For all of the lesions, the RFA needle was inserted with ultrasound guidance, and the lesion was ablated for up to 25 minutes depending on the probe used; a margin of up to 1 cm of normal hepatic parenchyma was included in the ablation.
The local recurrence rates have clearly decreased with advances in probe technology and improvements in intraoperative ultrasound. J Cancer Res Clin Oncol ;